Therapy of Type 2 Diabetes

Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity

Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860 · see citing works

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works

2018 ESC/ESH Guidelines for the management of arterial hypertension

Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286 · see citing works

The Physical Activity Guidelines for Americans

Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018) · JAMA · doi:10.1001/jama.2018.14854 · Cited by 9,755 · see citing works

2019 ESC/EAS Guidelines for the management of dyslipidaemias: <i>lipid modification to reduce cardiovascular risk</i>

Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961 · see citing works

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · see citing works

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · see citing works

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397 · see citing works

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140 · see citing works

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · see citing works

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382 · see citing works

A Randomized Trial of Intensive versus Standard Blood-Pressure Control

The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325 · see citing works

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · see citing works

Cardiovascular and renal outcomes with empagliflozin in heart failure

Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206 · see citing works

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · see citing works

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655 · see citing works

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · see citing works

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · see citing works

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes

The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908 · see citing works

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577 · see citing works

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · see citing works

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · see citing works

Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables

Ahlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335 · see citing works

Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · see citing works

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · see citing works

A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis

Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · see citing works

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997 · see citing works

Periodontitis and diabetes: a two-way relationship

Preshaw, P. M., Alba, A. L., Herrera, D., Jepsen, S. V., Konstantinidis, A. O., Makrilakis, K., & Taylor, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2342-y · Cited by 1,953 · see citing works

Sotagliflozin in patients with diabetes and recent worsening heart failure

Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868 · see citing works

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial

Hernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829 · see citing works

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · see citing works

Cardiovascular outcomes with ertugliflozin in type 2 diabetes

Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004967 · Cited by 1,514 · see citing works

Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report

Evert, A. B., Dennison, M., Gardner, C. D., Garvey, W. T., Lau, K. H. K., MacLeod, J., Mitri, J., Pereira, R. F., Rawlings, K., Robinson, S., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0014 · Cited by 1,496 · see citing works

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444 · see citing works

Liraglutide and renal outcomes in type 2 diabetes

Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253 · see citing works

Sotagliflozin in patients with diabetes and chronic kidney disease

Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030186 · Cited by 1,205 · see citing works

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial

Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114 · see citing works

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial

Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084 · see citing works

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Rosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080 · see citing works

COVID-19 and diabetes mellitus: from pathophysiology to clinical management

Lim, S. K., Bae, J. H., Kwon, H., & Nauck, M. A. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,024 · see citing works

Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial

Lean, M. E. J., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2019) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(19)30068-3 · Cited by 981 · see citing works

CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975 · see citing works

Practical recommendations for the management of diabetes in patients with COVID-19

Bornstein, S. R., Rubino, F., Khunti, K., Mingrone, G., Hopkins, D., Birkenfeld, A. L., Boehm, B. O., Amiel, S. A., Holt, R. I. G., Skyler, J. S., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30152-2 · Cited by 964 · see citing works

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

Neuen, B. L., Young, T., Heerspink, H. J. L., Neal, B., Perkovic, V., Billot, L., Mahaffey, K. W., Charytan, D. M., Wheeler, D. C., Arnott, C., et al. (2019) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(19)30256-6 · Cited by 893 · see citing works

Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes

Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829 · see citing works

Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial

(2016) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(16)30162-0 · Cited by 738 · see citing works

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial

Mosenzon, O., Wiviott, S. D., Cahn, A., Rozenberg, A., Yanuv, I., Goodrich, E. L., Murphy, S. A., Heerspink, H. J. L., Zelniker, T. A., Dwyer, J. P., et al. (2019) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(19)30180-9 · Cited by 684 · see citing works

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

Palmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679 · see citing works

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638 · see citing works

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial

Rosenstock, J., Kahn, S. E., Johansen, O. E., Zinman, B., Espeland, M. A., Woerle, H. J., Pfarr, E., Keller, A., Mattheus, M., Baanstra, D., et al. (2019) · JAMA · doi:10.1001/jama.2019.13772 · Cited by 612 · see citing works

Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study

Zaharia, O. P., Strassburger, K., Strom, A., Bönhof, G. J., Karusheva, Y., Antoniou, S., Bódis, K., Markgraf, D. F., Burkart, V., Müssig, K., et al. (2019) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(19)30187-1 · Cited by 600 · see citing works

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis

Bethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., et al. (2018) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(17)30412-6 · Cited by 599 · see citing works

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582 · see citing works

Efficacy and safety of degludec versus glargine in type 2 diabetes.

Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615692 · Cited by 574 · see citing works

Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus

Kato, E. T., Silverman, M. G., Mosenzon, O., Zelniker, T. A., Cahn, A., Furtado, R. H. M., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.040130 · Cited by 557 · see citing works

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

Wheeler, D. C., Stefánsson, B. V., Jongs, N., Chertow, G. M., Greene, T., Hou, F. F., McMurray, J. J. V., Correa-Rotter, R., Rossing, P., Toto, R. D., et al. (2021) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(20)30369-7 · Cited by 556 · see citing works

Metformin and Its Benefits for Various Diseases

Lv, Z., & Guo, Y. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00191 · Cited by 544 · see citing works

Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028198 · Cited by 536 · see citing works

10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetes—2021</i>

American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s010 · Cited by 495 · see citing works

Dietary and nutritional approaches for prevention and management of type 2 diabetes

Forouhi, N. G., Misra, A., Mohan, V., Taylor, R., & Yancy, W. S. (2018) · BMJ · doi:10.1136/bmj.k2234 · Cited by 493 · see citing works

Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data

Dennis, J., Shields, B. M., Henley, W., Jones, A. G., & Hattersley, A. T. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30087-7 · Cited by 461 · see citing works

Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes

Palmer, S. C., Mavridis, D., Nicolucci, A., Johnson, D. W., Tonelli, M. A., Craig, J. C., Maggo, J. K., Gray, V., Berardis, G. D., Ruospo, M., et al. (2016) · JAMA · doi:10.1001/jama.2016.9400 · Cited by 423 · see citing works

Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.

Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412 · see citing works

Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes

Zheng, S. L., Roddick, A., Agha-Jaffar, R., Shun-Shin, M. J., Francis, D. P., Oliver, N. S., & Meeran, K. M. (2018) · JAMA · doi:10.1001/jama.2018.3024 · Cited by 402 · see citing works

Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes

Griffin, S. J., Leaver, J. K., & Irving, G. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4337-9 · Cited by 398 · see citing works

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG outcome randomised, placebo-controlled trial

Cherney, D. Z. I., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., von Eynatten, M., & Wanner, C. (2017) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(17)30182-1 · Cited by 383 · see citing works

Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review

Khunti, K. K., Gomes, M. B., Pocock, S., Shestakova, M. V., Pintat, S., Fenici, P., Hammar, N., & Medina, J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13088 · Cited by 376 · see citing works

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes

Gough, S. C. L., Bode, B. W., Woo, V. C., Rodbard, H. W., Linjawi, S., Poulsen, P., Damgaard, L. H., & Buse, J. B. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70174-3 · Cited by 367 · see citing works

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): A 5-year, multicentre, randomised, double-blind trial

Matthews, D. R., Paldánius, P. M., Proot, P., Chiang, Y., Stumvoll, M., & Del Prato, S. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32131-2 · Cited by 364 · see citing works

Combined lifestyle factors and risk of incident type 2 diabetes and prognosis among individuals with type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies

Zhang, Y., Pan, X., Chen, J., Xia, L., Cao, A., Zhang, Y., Wang, J., Li, H., YANG, K. Y., Guo, K., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-04985-9 · Cited by 360 · see citing works

The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure

Thomas, M. C., & Cherney, D. Z. I. (2018) · Diabetologia · doi:10.1007/s00125-018-4669-0 · Cited by 351 · see citing works

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

Hartman, M. L., Sanyal, A. J., Loomba, R., Wilson, J. M., Nikooienejad, A., Bray, R., Karanikas, C. A., Duffin, K. L., Robins, D. A., & Haupt, A. (2020) · Diabetes Care · doi:10.2337/dc19-1892 · Cited by 351 · see citing works

Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction

Furtado, R. H. M., Bonaca, M. P., Raz, I., Zelniker, T. A., Mosenzon, O., Cahn, A., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.039996 · Cited by 335 · see citing works

Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor

Fralick, M., Schneeweiss, S., & Patorno, E. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1701990 · Cited by 334 · see citing works

Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

Vilsbøll, T., Bain, S. C., Leiter, L. A., Lingvay, I., Matthews, D., Simó, R., Helmark, I. C., Wijayasinghe, N., & Larsen, M. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13172 · Cited by 318 · see citing works

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

Sattar, N. A., McLaren, J. B., Kristensen, S. L., Preiss, D., & McMurray, J. J. V. (2016) · Diabetologia · doi:10.1007/s00125-016-3956-x · Cited by 310 · see citing works

Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group

Fleming, G. A., Petrie, J. R., Bergenstal, R. M., Holl, R. W., Peters, A. L., & Heinemann, L. (2020) · Diabetes Care · doi:10.2337/dci19-0062 · Cited by 306 · see citing works

Treatment of type 2 diabetes: challenges, hopes, and anticipated successes

Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 300 · see citing works

Understanding the mechanisms of reversal of type 2 diabetes

Taylor, R., Al-Mrabeh, A., & Sattar, N. (2019) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(19)30076-2 · Cited by 299 · see citing works

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial

Vaccaro, O., Masulli, M., Nicolucci, A., Bonora, E., Del Prato, S., Maggioni, A. P., Rivellese, A. A., Squatrito, S., Giorda, C. B., Sesti, G., et al. (2017) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(17)30317-0 · Cited by 292 · see citing works

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial

Mahaffey, K. W., Jardine, M. J., Bompoint, S., Cannon, C. P., Neal, B., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042007 · Cited by 291 · see citing works

SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials

Puckrin, R., Saltiel, M., Reynier, P., Azoulay, L., Yu, O. H. Y., & Filion, K. B. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1116-0 · Cited by 284 · see citing works

Metformin in cancer

Mallik, R., & Chowdhury, T. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.023 · Cited by 266 · see citing works

The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials

Min, T., & Bain, S. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00981-0 · Cited by 261 · see citing works

Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trials

Monami, M., Åhrén, B., Dicembrini, I., & Mannucci, E. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12000 · Cited by 259 · see citing works

Safety issues with glucagon‐like peptide‐1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): <scp>D</scp> ata from randomized controlled trials

Monami, M., Nreu, B., Scatena, A., Cresci, B., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12926 · Cited by 243 · see citing works

SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System

Fadini, G. P., Bonora, B. M., & Avogaro, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4301-8 · Cited by 242 · see citing works

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

Storgaard, H., Gluud, L. L., Bennett, C., Grøndahl, M. F. G., Christensen, M., Knop, F. K., & Vilsbøll, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166125 · Cited by 240 · see citing works

Benefits of the Mediterranean diet: Epidemiological and molecular aspects

Serra‐Majem, L., Román‐Viñas, B., Sánchez‐Villegas, A., Guasch‐Ferré, M., Corella, D., & Vecchia, C. L. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.06.001 · Cited by 240 · see citing works

Identification of barriers to insulin therapy and approaches to overcoming them

Russell‐Jones, D., Pouwer, F., & Khunti, K. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13132 · Cited by 238 · see citing works

Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies

Li, L., Li, S., Deng, K., Liu, J., Vandvik, P. O., Zhao, P., Zhang, L., Shen, J., Bała, M. M., Sohani, Z. N., et al. (2016) · BMJ · doi:10.1136/bmj.i610 · Cited by 237 · see citing works

Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes

Diamant, M., Nauck, M. A., Shaginian, R. M., Malone, J. K., Cleall, S., Reaney, M. D., de Vries, D., Hoogwerf, B. J., MacConell, L., Wolffenbuttel, B. H. R., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0876 · Cited by 229 · see citing works

Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease

Yurista, S. R., Chong, C., Badimón, J. J., Kelly, D. P., de Boer, R. A., & Westenbrink, B. D. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.12.065 · Cited by 226 · see citing works

Mortality risk among sulfonylureas: a systematic review and network meta-analysis

Simpson, S. H., Lee, J., Choi, S., Vandermeer, B., Abdelmoneim, A. S., & Featherstone, T. R. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70213-x · Cited by 222 · see citing works

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

Frias, J. P., Nauck, M. A., Van, J., Benson, C., Bray, R., Cui, X., Milicevic, Z., Urva, S., Haupt, A., & Robins, D. A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13979 · Cited by 208 · see citing works

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)

Cannon, C. P., McGuire, D. K., Pratley, R. E., Dagogo-Jack, S. E., Mancuso, J. P., Huyck, S. B., Charbonnel, B. H., Shih, W., Gallo, S., MASIUKIEWICZ, U. S., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.08.016 · Cited by 203 · see citing works

Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial

Billings, L. K., Doshi, A., Gouet, D., Oviedo, A., Rodbard, H. W., Tentolouris, N., Grøn, R., Halladin, N., & Jódar, E. (2018) · Diabetes Care · doi:10.2337/dc17-1114 · Cited by 196 · see citing works

Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review

Thiruvenkatarajan, V., Meyer, E. J., Nanjappa, N., van Wijk, R. M. A. W., & Jesudason, D. R. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2019.03.028 · Cited by 195 · see citing works

Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies

Azoulay, L., & Suissa, S. (2017) · Diabetes Care · doi:10.2337/dc16-1943 · Cited by 195 · see citing works

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3a): the DERIVE Study

Fioretto, P., Del Prato, S., Buse, J. B., Goldenberg, R., Giorgino, F., Reyner, D., Langkilde, A. M., Sjöström, C. D., Sartipy, P., & On Behalf of the DERIVE Study Investigators (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13413 · Cited by 195 · see citing works

Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England

Khunti, K. K., Knighton, P., Zaccardi, F., Bakhai, C., Barron, E., Holman, N., Kar, P. S., Meace, C., Sattar, N. A., Sharp, S. J., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00050-4 · Cited by 192 · see citing works

Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy ( VERTIS MET )

Rosenstock, J., Frías, J. P., Páll, D., Charbonnel, B. H., Pascu, R., Saur, D., Darekar, A., Huyck, S. B., Shi, H. H., Lauring, B. P., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13103 · Cited by 184 · see citing works

Sodium‐glucose co‐transporter‐2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta‐analysis of randomized controlled trials

Liu, J., Li, L., Li, S., Wang, Y., Qin, X., Deng, K., Liu, Y., Zou, K., & Sun, X. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14075 · Cited by 179 · see citing works

Resistance Exercise Intensity is Correlated with Attenuation of HbA1c and Insulin in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

Liu, Y., Ye, W., Chen, Q., Zhang, Y., Kuo, C.-H., & Korivi, M. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16010140 · Cited by 176 · see citing works

Cardiorespiratory fitness, muscular strength and risk of type 2 diabetes: a systematic review and meta-analysis

Tarp, J., Støle, A. P., Blond, K., & Grøntved, A. (2019) · Diabetologia · doi:10.1007/s00125-019-4867-4 · Cited by 173 · see citing works

Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial

on behalf of the VERTIS CV Investigators, Cherney, D. Z. I., Charbonnel, B. H., Cosentino, F., Dagogo-Jack, S. E., McGuire, D. K., Pratley, R. E., Shih, W., Frederich, R. C., Maldonado, M., et al. (2021) · Diabetologia · doi:10.1007/s00125-021-05407-5 · Cited by 170 · see citing works

Lack of evidence for a harmful effect of sodium‐glucose co‐transporter 2 ( SGLT2 ) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta‐analysis of randomized controlled trials

Tang, H., Li, D., Zhang, J. J., Hsu, Y., Wang, T., Zhai, S., & Song, Y. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12742 · Cited by 167 · see citing works

Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function

Lazarus, B., Wu, A., Shin, J., Sang, Y., Alexander, G. C., Secora, A. M., Inker, L. A., Coresh, J., Chang, A. R., & Grams, M. E. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.0292 · Cited by 166 · see citing works

Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population‐based study of older women and men with diabetes

Lega, I. C., Bronskill, S. E., Campitelli, M. A., Guan, J., Stall, N. M., Lam, K., McCarthy, L. M., Gruneir, A., & Rochon, P. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13820 · Cited by 166 · see citing works

The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes

Wilson, J. M., Nikooienejad, A., Robins, D. A., Roell, W. C., Riesmeyer, J. S., Haupt, A., Duffin, K. L., Taskinen, M., & Ruotolo, G. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14174 · Cited by 164 · see citing works

Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study

for the CORONADO investigators, Wargny, M., Potier, L., Gourdy, P., Pichelin, M., Amadou, C., Benhamou, P., Bonnet, J., Bordier, L., Bourron, O., et al. (2021) · Diabetologia · doi:10.1007/s00125-020-05351-w · Cited by 162 · see citing works

Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial

Inzucchi, S. E., Iliev, H., Pfarr, E., & Zinman, B. (2018) · Diabetes Care · doi:10.2337/dc17-1551 · Cited by 162 · see citing works

Comparative risk of genital infections associated with sodium‐glucose co‐transporter‐2 inhibitors

Dave, C. V., Schneeweiß, S., & Patorno, E. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13531 · Cited by 161 · see citing works

Efficacy of the Telemedical Lifestyle intervention Program TeLiPro in Advanced Stages of Type 2 Diabetes: A Randomized Controlled Trial

Kempf, K., Altpeter, B., Berger, J., Reuß, O., Fuchs, M., Schneider, M., Gärtner, B., Niedermeier, K., & Martin, S. (2017) · Diabetes Care · doi:10.2337/dc17-0303 · Cited by 160 · see citing works

Anticancer Activity of Metformin: A Systematic Review of the Literature

Aljofan, M., & Riethmacher, D. (2019) · Future Science OA · doi:10.2144/fsoa-2019-0053 · Cited by 160 · see citing works

Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis

Usman, M. S., Siddiqi, T. J., Memon, M. M., Khan, M. S., Rawasia, W. F., Talha Ayub, M., Sreenivasan, J., & Golzar, Y. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318755531 · Cited by 160 · see citing works

Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: A meta-analysis based on cardiovascular outcomes trials

Abd El Aziz, M., Cahyadi, O., Meier, J. J., Schmidt, W. E., & Nauck, M. A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13924 · Cited by 160 · see citing works

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Leiter, L. A., Bain, S. C., Hramiak, I., Jódar, E., Madsbad, S., Gondolf, T., Hansen, T., Holst, I., & Lingvay, I. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0871-8 · Cited by 159 · see citing works

Physical Exercise as Therapy for Type 2 Diabetes Mellitus: From Mechanism to Orientation

Yang, D., Yang, Y., Li, Y., & Han, R. (2019) · Annals of Nutrition and Metabolism · doi:10.1159/000500110 · Cited by 157 · see citing works

Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials

Mann, J. F. E., Hansen, T., Idorn, T., Leiter, L. A., Marso, S. P., Rossing, P., Seufert, J., Tadayon, S., & Vilsbøll, T. (2020) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(20)30313-2 · Cited by 157 · see citing works

Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases

Xie, Y., Bowe, B. C., Gibson, A. K., McGill, J. B., Maddukuri, G. S., Yan, Y., & Al‐Aly, Z. (2020) · Diabetes Care · doi:10.2337/dc20-1890 · Cited by 155 · see citing works

Faster‐acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart

Heise, T., Hövelmann, U., Brøndsted, L., Adrian, C. L., Nosek, L., & Haahr, H. L. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12468 · Cited by 150 · see citing works

DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality

on behalf of the DEVOTE Study Group, Pieber, T. R., Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pratley, R. E., Woo, V. C., Heller, S. R., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4422-0 · Cited by 150 · see citing works

GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis

Karagiannis, T., Tsapas, A., Athanasiadou, E., Avgerinos, I., Liakos, A., Matthews, D. R., & Bekiari, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108737 · Cited by 146 · see citing works

The Association between Sulfonylurea Use and All-Cause and Cardiovascular Mortality: A Meta-Analysis with Trial Sequential Analysis of Randomized Clinical Trials

Rados, D. V., Pinto, L. C., Remonti, L. R., Leitão, C. B., & Gross, J. L. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001992 · Cited by 143 · see citing works

Sodium‐glucose cotransporter 2 ( SGLT2 ) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta‐analysis

Ruanpeng, D., Ungprasert, P., Sangtian, J., & Harindhanavudhi, T. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2903 · Cited by 139 · see citing works

Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A B ayesian meta‐analysis of survival data

Bain, S., Druyts, E., Balijepalli, C., Baxter, C. A., Currie, C. J., Das, R., Donnelly, R., Khunti, K., Langerman, H., Leigh, P., et al. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12821 · Cited by 132 · see citing works

Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid

Tasanen, K., Varpuluoma, O., & Nishie, W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01238 · Cited by 126 · see citing works

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

Verma, S., Mazer, C. D., FITCHETT, D. H., Inzucchi, S. E., Pfarr, E., George, J. T., & Zinman, B. (2018) · Diabetologia · doi:10.1007/s00125-018-4644-9 · Cited by 125 · see citing works

Metformin in breast cancer: preclinical and clinical evidence

De, A., & Kuppusamy, G. (2019) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2019.06.003 · Cited by 124 · see citing works

Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study

Abrahami, D., Douros, A., Yin, H., Yu, O. H. Y., Renoux, C., Bitton, A., & Azoulay, L. (2018) · BMJ · doi:10.1136/bmj.k872 · Cited by 122 · see citing works

Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis

Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Hu, N., Juurlink, D. N., Paterson, J. M., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.1522 · Cited by 120 · see citing works

Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: The ONSET 2 trial

Bowering, K., Case, C., Harvey, J., Reeves, M., Sampson, M., Strzinek, R., Bretler, D.-M., Bang, R. B., & Bode, B. W. (2017) · Diabetes Care · doi:10.2337/dc16-1770 · Cited by 119 · see citing works

Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure

Sinha, B., & Ghosal, S. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.02.014 · Cited by 113 · see citing works

Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes

Tkáč, I., & Raz, I. (2016) · Diabetes Care · doi:10.2337/dc15-1707 · Cited by 112 · see citing works

Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6

Nauck, M. A., & Quast, D. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645566 · Cited by 112 · see citing works

Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine ( L antus®) in patients with type 2 diabetes who were insulin‐naïve or previously treated with insulin glargine: a randomized, double‐blind controlled trial (the ELEMENT 2 study)

Rosenstock, J., Hollander, P. A., Bhargava, A., Ilag, L. L., Pollom, R. K., Zielonka, J., Huster, W. J., & PRINCE, M. J. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12482 · Cited by 111 · see citing works

Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: A meta-analysis

Wang, R., Song, Y., Yan, Y., & Ding, Z. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.10.006 · Cited by 108 · see citing works

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study

Hollander, P. A., Liu, J., Hill, J., Johnson, J. R., Jiang, Z. W., Golm, G. T., Huyck, S. B., Terra, S. G., Mancuso, J. P., Engel, S. S., et al. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0354-4 · Cited by 107 · see citing works

Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research

Levin, P. A., Nguyen, H., Wittbrodt, E., & Kim, S. C. (2017) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s130834 · Cited by 107 · see citing works

Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation

McGovern, A. P., Hogg, M., Shields, B. M., Sattar, N. A., Holman, R. R., Pearson, E. R., Hattersley, A. T., Jones, A. G., & Dennis, J. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001238 · Cited by 106 · see citing works

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial

Ahmann, A., Rodbard, H. W., Rosenstock, J., Lahtela, J. T., Loredo, L. D., Tornøe, K., Boopalan, A., Nauck, M. A., & on behalf of the NN2211‐3917 Study Group (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12539 · Cited by 105 · see citing works

Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial

Verma, S., Bhatt, D. L., Bain, S. C., Buse, J. B., Mann, J. F. E., Marso, S. P., Nauck, M. A., Poulter, N. R., Pratley, R. E., Zinman, B., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.033898 · Cited by 105 · see citing works

Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials

Monami, M., Nreu, B., Zannoni, S., Lualdi, C., & Mannucci, E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.04.017 · Cited by 103 · see citing works

Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study

Aronson, R., Frías, J. P., Goldman, A., Darekar, A., Lauring, B. P., & Terra, S. G. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13251 · Cited by 99 · see citing works

GLP-1 receptor agonists and risk of cancer in type 2 diabetes: An updated meta-analysis of randomized controlled trials

Cao, C., Yang, S., & Zhou, Z. (2019) · Endocrine · doi:10.1007/s12020-019-02055-z · Cited by 99 · see citing works

Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure–Related Outcomes: Insights From the EXSCEL Trial

Fudim, M., White, J., Pagidipati, N. J., Lokhnygina, Y., Wainstein, J., Murin, J., Iqbal, N., Öhman, P., Lopes, R. D., Reicher, B., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.041659 · Cited by 99 · see citing works

Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta‐analysis

Mantsiou, C., Karagiannis, T., Kakotrichi, P., Malandris, K., Avgerinos, I., Liakos, A., Tsapas, A., & Bekiari, E. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14108 · Cited by 98 · see citing works

Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis

Hemmingsen, B., Schroll, J. B., Wetterslev, J., Gluud, C. N., Vaag, A. A., Sonne, D. P., Lundstrøm, L. H., & Almdal, T. (2014) · CMAJ Open · doi:10.9778/cmajo.20130073 · Cited by 97 · see citing works

Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis

Pinto, L. C. F., Rados, D. R. V., Barkan, S. S., Leitão, C. B., & Gross, J. L. (2018) · Scientific Reports · doi:10.1038/s41598-017-19055-6 · Cited by 95 · see citing works

A prospective study of type 2 diabetes, metformin use, and risk of breast cancer

Park, Y., Bookwalter, D. B., O’Brien, K. M., Jackson, C. L., Weinberg, C. R., & Sandler, D. P. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.12.008 · Cited by 95 · see citing works

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review

Rådholm, K., Wu, J. H. Y., Wong, M. G., Foote, C., Fulcher, G. R., Mahaffey, K. W., Perkovic, V., & Neal, B. C. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.03.027 · Cited by 94 · see citing works

Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride

Patorno, E., Schneeweiß, S., Gopalakrishnan, C., Martin, D., & Franklin, J. M. (2019) · Diabetes Care · doi:10.2337/dc19-0069 · Cited by 94 · see citing works

Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies

Linnebjerg, H., Lam, E. C. Q., Seger, M. E., Coutant, D. E., Chua, L., Chong, C. L., Ferreira, M. M., Soon, D., & Zhang, X. (2015) · Diabetes Care · doi:10.2337/dc14-2623 · Cited by 94 · see citing works

Goal-Based Shared Decision-Making: Developing an Integrated Model

Elwyn, G., & Vermunt, N. (2019) · Journal of Patient Experience · doi:10.1177/2374373519878604 · Cited by 93 · see citing works

Sodium‐glucose co‐transporter type‐2 inhibitors: pharmacology and peri‐operative considerations

Milder, D. A., Milder, T. Y., & Kam, P. C. A. (2018) · Anaesthesia · doi:10.1111/anae.14251 · Cited by 91 · see citing works

Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis

Piccoli, G. F., Mesquita, L. A., Stein, C., Aziz, M. M., Zoldan, M., Degobi, N. A. H., Spiazzi, B. F., Junior, G. L. L., Colpani, V., & Gerchman, F. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa891 · Cited by 91 · see citing works

Efficacy and safety of short- and long-acting glucagon-like peptide 1 receptor agonists on a background of basal insulin in type 2 diabetes: a meta-analysis.

Huthmacher, J. A., Meier, J. J., & Nauck, M. A. (2020) · Diabetes Care · doi:10.2337/dc20-0498 · Cited by 91 · see citing works

Oral semaglutide for type 2 diabetes: A systematic review and meta‐analysis

Avgerinos, I., Michailidis, T., Liakos, A., Karagiannis, T., Matthews, D. R., Τσάπας, Α., & Bekiari, E. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13899 · Cited by 88 · see citing works

Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes

Zou, C., Liu, X., Sang, Y., Wang, B., & Liang, J. (2019) · Medicine · doi:10.1097/md.0000000000018245 · Cited by 87 · see citing works

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

Zhou, Z., Jardine, M., Perkovic, V., Matthews, D. R., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Desai, M. G., Oh, R., Simpson, R., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4955-5 · Cited by 82 · see citing works

SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis

Seidu, S., Kunutsor, S. K., Cos, X., Gillani, S., & Khunti, K. (2018) · Primary Care Diabetes · doi:10.1016/j.pcd.2018.02.001 · Cited by 82 · see citing works

Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials

Dicembrini, I., Nreu, B., Scatena, A., Andreozzi, F., Sesti, G., Mannucci, E., & Monami, M. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-1031-9 · Cited by 81 · see citing works

The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study

on behalf of the ADVANCE Collaborative Group, Oshima, M., Jun, M., Ohkuma, T., Toyama, T., Wada, T., Cooper, M. E., Hadjadj, S., Hamet, P., Harrap, S. B., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4948-4 · Cited by 81 · see citing works

Mortality risk with preadmission metformin use in patients with COVID‐19 and diabetes: A meta‐analysis

Kow, C. S., & Hasan, S. S. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26498 · Cited by 81 · see citing works

Drug repurposing to overcome resistance to various therapies for colorectal cancer

Fong, W., & To, K. K. W. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03134-0 · Cited by 81 · see citing works

Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study

Guja, C., Frías, J. P., Somogyi, A., Jabbour, S. A., Wang, H., Hardy, E., & Rosenstock, J. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13266 · Cited by 79 · see citing works

Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta‐analysis

Li, X., Li, T., Cheng, Y., Lu, Y., Xue, M., Xu, L., Liu, X., Yu, X., Sun, B., & Chen, L. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3170 · Cited by 79 · see citing works

SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes

Donnan, K., & Segar, L. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.01.002 · Cited by 76 · see citing works

A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease

Dougherty, J. A., Guirguis, E. H., & Thornby, K. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020935105 · Cited by 74 · see citing works

Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL : 1‐year patient‐level meta‐analysis of the EDITION clinical studies in people with type 2 diabetes

Ritzel, R. A., Roussel, R., Giaccari, A., Vora, J. P., Brulle-Wohlhueter, C., & Yki‐Järvinen, H. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13105 · Cited by 73 · see citing works

Impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: a randomized trial.

Rosenstock, J., Nino, A., Soffer, J., Erskine, L., Acusta, A., Dole, J., Carr, M. C., Mallory, J., & Home, P. (2020) · Diabetes Care · doi:10.2337/dc19-2316 · Cited by 73 · see citing works

Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies

Hidayat, K., Du, X., & Shi, B. (2019) · Osteoporosis International · doi:10.1007/s00198-019-04968-x · Cited by 71 · see citing works

Risk of dipeptidyl peptidase-4 (DPP-4) inhibitors on site-specific cancer: A systematic review and meta-analysis

Overbeek, J. A., Bakker, M., van der Heijden, A. A. W. A., van Herk‐Sukel, M. P. P., Herings, R. M. C., & Nijpels, G. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3004 · Cited by 71 · see citing works

Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis

Liu, J., Li, L., Deng, K., Xu, C., Busse, J. W., Vandvik, P. O., Li, S., Guyatt, G. H., & Sun, X. (2017) · BMJ · doi:10.1136/bmj.j2499 · Cited by 70 · see citing works

Efficacy and safety over 2 Years of exenatide plus dapagliflozin in the DURATION-8 study: a multicenter, double-blind, phase 3, randomized controlled trial

Jabbour, S. A., Frías, J. P., Ahmed, A., Hardy, E., Choi, J., Sjöström, C. D., & Guja, C. (2020) · Diabetes Care · doi:10.2337/dc19-1350 · Cited by 69 · see citing works

Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study

Pasternak, B., Wintzell, V., Eliasson, B., Svensson, A., Franzén, S., Guðbjörnsdóttir, S., Hveem, K., Jonasson, C., Melbye, M., Svanström, H., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2088 · Cited by 68 · see citing works

The effects of popular diets on type 2 diabetes management

Chester, B., Babu, J. R., Greene, M. W., & Geetha, T. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3188 · Cited by 65 · see citing works

Impact of intensive lifestyle intervention on disability-free life expectancy: the Look AHEAD study

Gregg, E. W., Lin, J., Bardenheier, B., Chen, H., Rejeski, W. J., Zhuo, X., Hergenroeder, A. L., Kritchevsky, S. B., Peters, A. L., Wagenknecht, L. E., et al. (2018) · Diabetes Care · doi:10.2337/dc17-2110 · Cited by 64 · see citing works

Using real‐world data to evaluate the association of incretin‐based therapies with risk of acute pancreatitis: a meta‐analysis of 1 324 515 patients from observational studies

Wang, T., Wang, F., Gou, Z., Tang, H., Li, C., Shi, L., & Zhai, S. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12386 · Cited by 62 · see citing works

The role of an anti-diabetic drug metformin in the treatment of endocrine tumors

Thakur, S., Daley, B., & Kłubo-Gwieździńska, J. (2019) · Journal of Molecular Endocrinology · doi:10.1530/jme-19-0083 · Cited by 62 · see citing works

Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial

Perkovic, V., Toto, R., Cooper, M. E., Mann, J. F. E., Rosenstock, J., McGuire, D. K., Kahn, S. E., Marx, N., Alexander, J. H., Zinman, B., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0279 · Cited by 62 · see citing works

Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride

Köhler, S., Kaspers, S., Salsali, A., Zeller, C., & Woerle, H. J. (2018) · Diabetes Care · doi:10.2337/dc17-1525 · Cited by 58 · see citing works

Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: a trial-level meta-analysis including 51 713 individuals

Huang, C., & Lee, J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14159 · Cited by 57 · see citing works

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

Husain, M., Bain, S. C., Holst, A. G., Mark, T., Rasmussen, S., & Lingvay, I. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01106-4 · Cited by 55 · see citing works

The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials

Ling, J., Peng, C., Ge, L., Ding-hua, Z., Shi, A., Tian, J., Chen, Y., Li, X., Zhang, J., & Yang, K. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1222-z · Cited by 55 · see citing works

Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis

Kar, D., Gillies, C. L., Nath, M., Khunti, K. K., Davies, M. J., & Seidu, S. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01293-x · Cited by 53 · see citing works

Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update

Salah, H. M., Al'Aref, S. J., Khan, M. S., Al-Hawwas, M., Vallurupalli, S., Mehta, J. L., Mounsey, J. P., Greene, S. J., McGuire, D. K., Lopes, R. D., et al. (2021) · American Heart Journal · doi:10.1016/j.ahj.2020.12.007 · Cited by 52 · see citing works

Does lower limb amputation concern all SGLT2 inhibitors?

Scheen, A. J. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0001-9 · Cited by 50 · see citing works

Objectively Assessed Physical Activity and Weight Loss Maintenance among Individuals Enrolled in a Lifestyle Intervention

Unick, J. L., Gaussoin, S. A., Hill, J. O., Jakicic, J. M., Bond, D. S., Hellgren, M. I., Johnson, K., Peters, A. L., Coday, M., Kitzman, D. W., et al. (2017) · Obesity · doi:10.1002/oby.21971 · Cited by 48 · see citing works

Fournier's gangrene and sodium‐glucose co‐transporter‐2 inhibitors: A meta‐analysis of randomized controlled trials

Silverii, G. A., Dicembrini, I., Monami, M., & Mannucci, E. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13900 · Cited by 48 · see citing works

Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis

Bonora, B. M., Avogaro, A., & Fadini, G. P. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01515-6 · Cited by 48 · see citing works

Metformin use and prostate cancer risk

Feng, Z., Zhou, X., Liu, N., Wang, J., Chen, X., & Xu, X. (2019) · Medicine · doi:10.1097/md.0000000000014955 · Cited by 47 · see citing works

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial

Inzucchi, S. E., Khunti, K. K., FITCHETT, D. H., Wanner, C., Mattheus, M., George, J. T., Ofstad, A. P., & Zinman, B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa321 · Cited by 46 · see citing works

Short and medium‐term efficacy of sodium glucose co‐transporter‐2 (SGLT‐2) inhibitors: A meta‐analysis of randomized clinical trials

Monami, M., Liïstro, F., Scatena, A., Nreu, B., & Mannucci, E. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13221 · Cited by 45 · see citing works

Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin

Hollander, P. A., Hill, J., Johnson, J. R., Jiang, Z. W., Golm, G. T., Huyck, S. B., Terra, S. G., Mancuso, J. P., Engel, S. S., Lauring, B. P., et al. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1583450 · Cited by 45 · see citing works

Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis

Mishriky, B. M., Tanenberg, R. J., Sewell, K. B., & Cummings, D. M. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.01.017 · Cited by 44 · see citing works

Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials

Cherney, D. Z. I., Heerspink, H. J. L., Frederich, R. C., Maldonado, M., Liu, J., Pong, A., Xu, Z. J., Patel, S. M., Hickman, A., Mancuso, J. P., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05133-4 · Cited by 43 · see citing works

Preeclampsia and Obesity—The Preventive Role of Exercise

Poniedziałek‐Czajkowska, E., Mierzyński, R., & Leszczyńska‐Gorzelak, B. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20021267 · Cited by 69 · see citing works

Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon‐like peptide‐1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow‐Up Registry

Jung, H., Tittel, S. R., Schloot, N. C., Heitmann, E., Otto, T., Lebrec, J., Pavel, M., & Lanzinger, S. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15038 · Cited by 23 · see citing works

Evaluation of the Impact of Mobile Health App Vitadio in Patients With Type 2 Diabetes: Randomized Controlled Trial

Bretschneider, M. P., Kolasińska, A. B., Šomvárska, L., Klásek, J., Mareš, J., & Schwarz, P. E. (2025) · Journal of Medical Internet Research · doi:10.2196/68648 · Cited by 15 · see citing works

Long-Term Effects of Transtheoretical Model-Based Lifestyle Intervention on Self-efficacy and Self-management in Patients with Type 2 Diabetes — Randomised Controlled Trial

Dunkel, A., von Storch, K., Hochheim, M., Zank, S., Polidori, M. C., & Woopen, C. (2024) · International Journal of Behavioral Medicine · doi:10.1007/s12529-024-10323-0 · Cited by 13 · see citing works

Long-term effects of a telemedically-assisted lifestyle intervention on glycemic control in patients with type 2 diabetes – A two-armed randomised controlled trial in Germany

Dunkel, A., von Storch, K., Hochheim, M., Zank, S., Polidori, M. C., & Woopen, C. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01290-6 · Cited by 14 · see citing works

Cardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta‐Analysis

Shi, S., Li, X., Chen, Y., Li, J., & Dai, Y. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70044 · Cited by 4 · see citing works

Diabetes im Krankenhaus

Müssig, K., Gallwitz, B., Haak, T., Kellerer, M., & Siegel, E. G. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2251-2772 · Cited by 3 · see citing works

Diabetes im Krankenhaus

Müssig, K., Gallwitz, B., Haak, T., Kellerer, M., & Siegel, E. G. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2312-1160 · Cited by 3 · see citing works

Diabetes in Hospitals

Müssig, K., Gallwitz, B., Haak, T., Kellerer, M., & Siegel, E. G. (2025) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2490-5208 · Cited by 1 · see citing works

Preliminary insight into the potential role of Leptin Receptor Polymorphisms in Type 2 Diabetes Risk: case-control study and bioinformatics analysis

Akbar-Abad, M. S., Majidpour, M., Keykha, F., Maleki, M., Piroozan, Y., Saravani, R., Zandhaghighi, M., Shahriari, H., & Sargazi, S. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01617-5 · Cited by 1 · see citing works

Utilizing Semaglutide for Addressing Type-2 Diabetes and Obesity

Gupta, R., & Sharma, S. (2025) · Current Signal Transduction Therapy · doi:10.2174/0115743624346660250317013032 · Cited by 1 · see citing works

Erklärtes Ziel: Remission des Typ-2-Diabetes

Kempf, K., & Röhling, M. (2023) · Info Diabetologie · doi:10.1007/s15034-023-4536-z

Therapie des Typ-2-Diabetes

Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Reuter, H., & Siegel, E. G. (2020) · Diabetologie und Stoffwechsel · doi:10.1055/a-1193-3793 · Cited by 21 · see citing works

Praxisempfehlungen DDG/DGIM

Landgraf, R., Kellerer, M., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., Hm, R., et al. (2016) · Diabetologie und Stoffwechsel · doi:10.1055/s-0042-114151 · Cited by 3 · see citing works

[National practice guideline therapy of type 2 diabetes].

Landgraf, R. (2014) · PubMed · Cited by 5 · see citing works

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kellerer, M., & Siegel, E. G. (2013) · Diabetologie und Stoffwechsel · doi:10.1055/s-0033-1355642 · Cited by 4 · see citing works

Accepted

Pharmacol, B. J. C., & Lub, R. (1997)